Alzheimer's Intelligence · Powered by PanaceaIntel
Clear intelligence on a complicated disease.
PatientSpotlight tracks the science, treatments, and lived experience of Alzheimer's disease — and translates it into something you can actually use.
Latest Signals
All signals →Blood-based biomarkers move from research to clinical workflow
A blood draw is becoming the entry point to the Alzheimer's diagnostic pathway — not the endpoint.
Plasma p-tau217 assays are being adopted as a triage step before PET or CSF confirmation in specialty memory clinics.
Lecanemab uptake constrained by infusion infrastructure, not demand
The first approved disease-modifying therapy is being throttled by logistics, not biology.
Real-world rollout of lecanemab is gated by infusion-chair capacity and MRI monitoring schedules — not by patient interest or prescriber willingness.
Donanemab introduces a finite-duration treatment model
Treatment may be a course rather than a chronic commitment. The downstream economics differ accordingly.
Donanemab's protocol allows treatment cessation once amyloid plaque clearance is confirmed — a meaningfully different model from indefinite biologic dosing.
Featured Insight
The anti-amyloid rollout is rate-limited by infrastructure, not science
Two years into the lecanemab and donanemab era, the binding constraints on access are not regulatory or clinical — they are operational.
Read the full analysis →
Key Snapshots
All snapshots →Disease-modifying therapies in Alzheimer's, as of Q2 2026
The current treatment landscape is narrow, the access constraints are operational, and the next material change is delivery format — not a new mechanism.
Two anti-amyloid antibodies have traditional FDA approval; subcutaneous formulations are advancing; the post-amyloid pipeline is portfolio-shaped.
Alzheimer's diagnostic pathways, as of Q2 2026
The diagnostic toolkit is broader than it was three years ago, but the post-diagnostic system has not scaled at the same pace.
Plasma biomarkers are entering routine workflows alongside established CSF and PET options, with confirmatory imaging still standard before disease-modifying therapy.
Alzheimer's regulatory and reimbursement landscape, as of Q2 2026
Regulatory clarity has improved; reimbursement clarity is still evolving; international access still varies meaningfully across major markets.
Two anti-amyloid antibodies have traditional FDA approval; CMS coverage operates under a coverage-with-evidence-development framework; international approvals diverge.
What this is
Research-grade intelligence, written to be read.
PatientSpotlight is an Alzheimer's intelligence publication. We cover what is changing in the disease — clinically, regulatorily, and operationally — and what those changes actually mean for patients, families, clinicians, and decision makers.
Our work is organized into four formats: Signals for early indicators worth watching, Insights for synthesis, Snapshots for landscape reference, and Explained for plain-language primers.
Powered by PanaceaIntel.